Pneumonia Vaccines Market by Type (Pneumococcal Conjugate and Pneumococcal Polysaccharide Vaccine), by Product (Prevnar 13, Synflorix, Pneumovax 23, and Others), by Sector (Public and Private Sector), by Age Group (Adults and Pediatrics) and by Distribution Channel (Distribution Partner Companies, Non-governmental Organizations, Public Health Agencies, Community Clinics and Others) - Global Opportunity Analysis and Industry Forecast 2022-2030.

Pneumonia Vaccines Market

Industry:  Life Sciences & Healthcare | Publish Date: Dec 2022 | No of Pages:  N/A | No. Tables:  N/A | No. Figures:  N/A

Market Definition:

The Pneumonia Vaccines Market size was valued at USD 8.76 billion in 2021 and is predicted to reach USD 15.46 billion by 2030 with a CAGR of 6.52% from 2022-2030.

Pneumonia vaccines protect paediatrics and adults against pneumococcal bacterial strains by stimulating the immune system. These vaccines prevent the spreading of pneumonia and further eliminate hospitalization & reduce the fatality rate. There are two types of vaccines available in the market: PPSV23 and PCV13. The former protects against 23 types of pneumococcal bacteria, while the latter is for 13 types. Besides, every year, pneumonia affects ~450 million people globally, which makes up 7% of the total world population and 4 million deaths globally, hence high caseload increases the demand for pneumonia vaccines. 

Market Dynamics and Trends:

Focus of various governments and non-government agencies such as UNICEF, GAVI, charitable trusts, and WHO towards vaccination is one of the major factors driving the market. For instance, in December 2020, Atlantic Health Partners announced the addition of Prevnar 13 to its vaccine program. The members of Atlantic Health had access to  Pfizer’s pneumococcal 13-valent conjugate vaccine from January 2021. Apart from this, various awareness programs conducted by several agencies related to vaccines along with a rise in prevalence of pneumococcal contaminations, mostly in countries such as India, Nigeria, Pakistan, the Democratic Republic of Congo, and Ethiopia further boost the demand for pneumonia vaccines.

Moreover, the COVID-19 outbreak had a positive impact on the market as these vaccines are applied in COVID-19 treatment. One of an articles in the Vaccine Journal, published in December 2021, titled 'Promising Expectations for Pneumococcal Vaccination, during COVID-19' represented that any underlying medical disease with pneumococcal strain increases the risk of severe pneumonia. Also, COVID-19 is currently considered as a primary risk factor for pneumonia. Furthermore, pneumonia is common in children with malnutrition or undernourishment. As per 2021 data of the WHO, ~150 million new cases of pneumonia occur annually among children younger than 5 years worldwide. Such a high caseload accelerates the requirement of vaccines against this disease.

However, higher costs and timelines associated with production of the vaccines and stringent approval guidelines restrain the revenue generation in the market. Conversely, development of the innovative protein-based vaccines such as PhtD monovalent and PhtD+dPly is expected to create lucrative growth opportunities in the coming future.

Market Segmentation and Scope of Study:

The global pneumonia vaccines market is segmented on the basis of type, product, sector, distribution channel, age group, and geography. Based on type, the market is bifurcated into pneumococcal conjugate and polysaccharide vaccines. Based on product, it is categorized into Prevnar 13, Synflorix, Pneumovax 23, and others. Based on sector, it is divided into public and private sectors. By age group, it is analyzed for pediatrics and adults. By distribution channel, it is segmented into distribution partner companies, non-governmental organizations (NGOs), public health agencies, community clinics and others. Geographical breakdown and analysis of each of the aforesaid classification includes regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

North America leads the market in terms of revenue generation owing to established healthcare infrastructure, high prevalence & mortality rate of pneumonia, high research funding by public agencies, and strong presence of leading players. For instance, funding from National Institutes for Health for pneumonia & influenza was ~USD 660 million from the FY 2013 to 2020. Strong presence of pipeline products and continuous developments by several U.S.-based players boost regional market growth. For instance, Merck received breakthrough therapy designation for its investigational V116 conjugate vaccine from the FDA in April 2022. While, in July 2021, Astellas Pharma with Affinivax, Inc. presented the results from phase 2 clinical trial of its ASP3772 vaccine for Streptococcus pneumoniae. 

Asia Pacific is projected to grow at a substantial CAGR due to increase in malnutrition cases in lower-income countries and strategies undertaken by public agencies. As per the report of the National Institute of India, published in June 2021, the estimated funding for pneumonia in 2019 was USD 146 million and it reached USD 223 million by 2020. Besides, Union Health Ministry India expanded pneumonia conjugate vaccines under its universal immunization program in January 2022. This initiative allowed the free availability of vaccines for children across India. 

Also, weakened immune response in patients due to  air pollution and smoking increases the risk of infection in this market. As per NIH 2020 data, the prevalence of consuming any tobacco product among males aged 15 and above was 40.2% in Malaysia, 39.7% in Thailand, 46.9% in South Korea, 28.3% in Singapore, 14.3% in Australia, 10.0% in Hong Kong.

Competitive Landscape:

Major key players operating in the pneumonia vaccines market include GlaxoSmithKline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Astellas Pharma Inc., Ltd. SK Bioscience and Walvax Biotechnology Co., Ltd. These players are involved in R&D for new product development and partnerships to broaden their portfolio.

For Instance, in June 2021, Pfizer’s PREVNAR 20 received the FDA approval for adults over 18 years. This new product prevents invasive disease and pneumonia caused by the 20 bacteria serotypes. Also, in July 2021, Merck received FDA approval for its VAXNEUVANCE that prevents invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 23F 19A, 19F, 18C, 22F, and 33F in 18 years and above adults.

KEY BENEFITS:

  • The pneumonia vaccines market report provides the quantitative analysis of the current market and estimations through 2022-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the pneumonia vaccines market trend including the current and future trends for depicting the prevalent investment pockets in the market.

  • The information related to key drivers, restraints and opportunities and their impact on the pneumonia vaccines market is provided in the report.

  • The competitive analysis of the market players along with their market share in the pneumonia vaccines market

  • The SWOT analysis and Porters Five Forces model is elaborated in the study.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ 

KEY MARKET SEGMENTS:

By Type 

  • Pneumococcal Conjugate Vaccine

  • Pneumococcal Polysaccharide Vaccine

  • Pneumonia Vaccines Marketby Product

By Product

  • Prevnar 13

  • Synflorix

  • Pneumovax 23

  • Others

By Sector

  • Public Sector

  • Private Sector

By Age Group

  • Adults

  • Pediatrics

By Distribution Channel

  • Distribution Partner Companies

  • Non-governmental Organizations (NGO)

  • Public Health Agencies

  • Community Clinics

  • Others

By Geography

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Rest of Asia-Pacific

  • RoW

    • UAE

    • Saudi Arabia

    • South Africa

    • Brazil

    • Remaining countries

KEY BENEFITS:

  • The pneumonia vaccines market report provides the quantitative analysis of the current market and estimations through 2022-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the pneumonia vaccines market trend including the current and future trends for depicting the prevalent investment pockets in the market.

  • The information related to key drivers, restraints and opportunities and their impact on the pneumonia vaccines market is provided in the report.

  • The competitive analysis of the market players along with their market share in the pneumonia vaccines market

  • The SWOT analysis and Porters Five Forces model is elaborated in the study.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ 

KEY MARKET SEGMENTS:

By Type 

  • Pneumococcal Conjugate Vaccine

  • Pneumococcal Polysaccharide Vaccine

  • Pneumonia Vaccines Marketby Product

By Product

  • Prevnar 13

  • Synflorix

  • Pneumovax 23

  • Others

By Sector

  • Public Sector

  • Private Sector

By Age Group

  • Adults

  • Pediatrics

By Distribution Channel

  • Distribution Partner Companies

  • Non-governmental Organizations (NGO)

  • Public Health Agencies

  • Community Clinics

  • Others

By Geography

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Rest of Asia-Pacific

  • RoW

    • UAE

    • Saudi Arabia

    • South Africa

    • Brazil

    • Remaining countries

KEY PLAYERS:

  • GlaxoSmithKline Plc

  • LG Chem Ltd.

  • Merck & Co., Inc.

  • Panacea Biotec Limited

  • Pfizer Inc.

  • Pnuvax Incorporated

  • Serum Institute of India Pvt. Ltd.

  • Astellas Pharma Inc. 

  • SK Bioscience

  • Walvax Biotechnology Co., Ltd.


Frequently Asked Questions
What will be the worth of pneumonia vaccines market by the end of 2030?

Global pneumonia vaccines market size was valued at USD 8.76 billion in 2021 and is predicted to reach USD 15.46 billion by 2030 with a CAGR of 6.52% from 2022-2030.

Which region is expected to hold the highest market share in pneumonia vaccines industry?

North America leads the market. In terms of revenue generation owing to established healthcare infrastructure, high prevalence & mortality rate of pneumonia, high research funding by public agencies, and strong presence of leading players.

Which are the top players in the pneumonia vaccines market?

GlaxoSmithKline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Astellas Pharma Inc., Ltd. SK Bioscience and Walvax Biotechnology Co., Ltd.

What are the market segments and scope of the study?

The global pneumonia vaccines market is segmented on the basis of type, product, sector, distribution channel, age group, and geography.

What are the challenges in the pneumonia vaccines market?

Higher costs and timelines associated with production of the vaccines and stringent approval guidelines restrain the revenue generation in the market.